JP2020530437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530437A5 JP2020530437A5 JP2019570982A JP2019570982A JP2020530437A5 JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5 JP 2019570982 A JP2019570982 A JP 2019570982A JP 2019570982 A JP2019570982 A JP 2019570982A JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5
- Authority
- JP
- Japan
- Prior art keywords
- neopeptides
- recombinant poxvirus
- neopeptide
- tumor
- poxvirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100296A JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305760 | 2017-06-21 | ||
| EP17305760.5 | 2017-06-21 | ||
| EP18305496.4 | 2018-04-23 | ||
| EP18305496 | 2018-04-23 | ||
| PCT/EP2018/066668 WO2018234506A2 (en) | 2017-06-21 | 2018-06-21 | PERSONALIZED VACCINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Division JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530437A JP2020530437A (ja) | 2020-10-22 |
| JP2020530437A5 true JP2020530437A5 (cg-RX-API-DMAC7.html) | 2023-07-05 |
| JP7334124B2 JP7334124B2 (ja) | 2023-08-28 |
Family
ID=62599637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570982A Active JP7334124B2 (ja) | 2017-06-21 | 2018-06-21 | 個別化ワクチン |
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11969462B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3641803A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7334124B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240113607A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111065406A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018287159B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3067405A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL271558B2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201912429RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018234506A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| JP7894215B2 (ja) * | 2019-01-03 | 2026-07-23 | エヴァクシオン・アクシェセルスケープ | ネオエピトープを標的とするワクチン |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113631185A (zh) * | 2019-02-27 | 2021-11-09 | 尼克塔治疗公司 | 用于治疗癌症的免疫治疗组合 |
| MX2022002417A (es) * | 2019-08-29 | 2022-03-22 | Astellas Pharma Inc | Virus vaccinia oncoliticos modificados geneticamente y metodos de uso de los mismos. |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN111303277A (zh) * | 2020-02-19 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN116656730B (zh) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法 |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
| WO2026044351A1 (en) * | 2024-08-28 | 2026-03-05 | The Council Of The Queensland Institute Of Medical Research | Hpv antigenic composition and uses thereof |
| WO2026108904A1 (zh) * | 2024-11-21 | 2026-05-28 | 北京立康生命科技有限公司 | 一种间隔肽及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| US7094412B2 (en) | 2001-12-10 | 2006-08-22 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| KR101121971B1 (ko) | 2003-07-22 | 2012-03-09 | 비바리스 | 부착성 또는 비부착성 조류 세포주를 이용한폭스바이러스의 생산 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| ATE477321T1 (de) | 2006-01-05 | 2010-08-15 | Transgene Sa | Aviäre telomerase reverse transkriptase |
| RU2489486C2 (ru) | 2006-06-20 | 2013-08-10 | Трансжене С.А. | Процесс получения поксвирусов и композиции поксвирусов |
| CL2008000249A1 (es) | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| AU2008250596C1 (en) | 2007-05-14 | 2010-11-25 | Bavarian Nordic A/S | Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines |
| CA2687304A1 (en) | 2007-05-15 | 2008-11-20 | Transgene S.A. | Signaling peptides |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| BRPI0811787B1 (pt) | 2007-07-03 | 2018-10-09 | Transgene Sa | usos de uma célula imortalizada e processo para imortalizar uma célula aviária |
| EP2212423B1 (en) | 2007-11-19 | 2015-02-11 | Transgene SA | Poxviral oncolytic vectors |
| DK2212345T3 (en) | 2007-11-19 | 2016-03-21 | Transgene Sa | Oncolytic poxvirus vectors |
| AU2009214768B2 (en) | 2008-02-12 | 2015-01-22 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
| EP2199400A1 (en) * | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| US9115402B2 (en) * | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| KR102022952B1 (ko) | 2011-08-05 | 2019-09-20 | 신라젠(주) | 백시니아 바이러스의 생산을 위한 방법 및 조성물 |
| MX364370B (es) * | 2012-07-12 | 2019-04-24 | Persimmune Inc | Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas. |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| US20160032396A1 (en) * | 2013-03-15 | 2016-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and Use of Circulating Nucleic Acid Tumor Markers |
| AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| JP6740127B2 (ja) * | 2013-12-06 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新生物ワクチン用製剤 |
| DK3142690T3 (da) | 2014-05-13 | 2022-05-09 | Bavarian Nordic As | Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| JP6913032B2 (ja) | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| TW201708536A (zh) | 2015-05-26 | 2017-03-01 | 艾法西斯公司 | 個人化的基於遞送載體之免疫療法及其用途 |
| TW202241500A (zh) * | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| EP3313975A4 (en) | 2015-06-24 | 2019-03-13 | Advaxis, Inc. | MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY |
| JP7114477B2 (ja) * | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| WO2017177207A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
-
2018
- 2018-06-21 KR KR1020247022788A patent/KR20240113607A/ko active Pending
- 2018-06-21 CN CN201880050941.2A patent/CN111065406A/zh active Pending
- 2018-06-21 KR KR1020207001211A patent/KR102684237B1/ko active Active
- 2018-06-21 AU AU2018287159A patent/AU2018287159B2/en active Active
- 2018-06-21 EP EP18731146.9A patent/EP3641803A2/en active Pending
- 2018-06-21 SG SG11201912429RA patent/SG11201912429RA/en unknown
- 2018-06-21 CA CA3067405A patent/CA3067405A1/en active Pending
- 2018-06-21 JP JP2019570982A patent/JP7334124B2/ja active Active
- 2018-06-21 WO PCT/EP2018/066668 patent/WO2018234506A2/en not_active Ceased
- 2018-06-21 US US16/625,239 patent/US11969462B2/en active Active
- 2018-06-21 IL IL271558A patent/IL271558B2/en unknown
-
2023
- 2023-04-13 US US18/299,858 patent/US20230277639A1/en active Pending
- 2023-06-19 JP JP2023100296A patent/JP2023123609A/ja active Pending
-
2025
- 2025-07-18 JP JP2025121773A patent/JP2025160281A/ja active Pending
-
2026
- 2026-04-20 US US19/652,341 patent/US20260232778A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102021585B1 (ko) | 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법 | |
| JP7486206B2 (ja) | 人工的に構築されたrna編集酵素による部位特異的rna編集および関連使用 | |
| JP5474816B2 (ja) | mRNA翻訳エンハンサーエレメントに関する組成物および方法 | |
| CN108251452A (zh) | 一种表达Cas9基因的转基因斑马鱼及其构建方法和应用 | |
| CA2983364A1 (en) | Compositions and methods for the treatment of nucleotide repeat expansion disorders | |
| JP2018532419A (ja) | CRISPR−Cas sgRNAライブラリー | |
| CN113227387B (zh) | 基于单细胞转录组开发aav载体和启动子的方法和材料 | |
| US6395872B1 (en) | Secreted neural adhesion proteins | |
| JP2005522225A (ja) | 亢進された遺伝子発現系 | |
| JPH07265085A (ja) | 組換えポックスウイルス | |
| CN117859703B (zh) | Anxa11基因的新突变致病位点C104G的敲入小鼠模型及其构建方法与应用 | |
| CN110885799A (zh) | 一种基于腺病毒的基因编辑方法 | |
| CN112899237A (zh) | Cdkn1a基因报告细胞系及其构建方法和应用 | |
| US9765305B2 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| CA3109429A1 (en) | Methods and compositions for producing a virus | |
| CN121548639A (zh) | 用于crispr干扰和激活的改进方法和组合物 | |
| KR101613457B1 (ko) | 고추 식물 유래 신규한 고추 난쟁이 엔도르나바이러스 유전자 | |
| KR940001265B1 (ko) | 프로모터, 그를 함유하는 플라스미드 및 재조합 아비폭스비루스 | |
| US6841347B1 (en) | In vivo construction of DNA libraries | |
| KR102955030B1 (ko) | 신규한 가이드 rna 및 이의 용도 | |
| CN119506355B (zh) | 一种用于重组痘病毒包装的载体系统及其应用 | |
| JP7034818B2 (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| WO2009144958A1 (ja) | 組換えウイルス、これを保持する大腸菌およびその製造法 | |
| RU2020101489A (ru) | Персонализированная вакцина | |
| Gite et al. | 35 Protein Truncation |